5.585
전일 마감가:
$5.28
열려 있는:
$5.25
하루 거래량:
1.05M
Relative Volume:
0.56
시가총액:
$993.36M
수익:
-
순이익/손실:
$-45.44M
주가수익비율:
-15.96
EPS:
-0.35
순현금흐름:
$-42.28M
1주 성능:
+3.62%
1개월 성능:
+47.36%
6개월 성능:
+157.37%
1년 성능:
+269.87%
Compass Therapeutics Inc Stock (CMPX) Company Profile
명칭
Compass Therapeutics Inc
전화
617-500-8099
주소
80 GUEST STREET, BOSTON
CMPX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
CMPX
Compass Therapeutics Inc
|
5.585 | 939.11M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 개시 | Canaccord Genuity | Buy |
| 2025-12-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-07-01 | 재개 | Raymond James | Outperform |
| 2025-04-02 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | 개시 | Guggenheim | Buy |
| 2025-02-19 | 개시 | Piper Sandler | Overweight |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 개시 | Jefferies | Buy |
| 2023-01-27 | 개시 | Stifel | Buy |
| 2022-05-23 | 재개 | H.C. Wainwright | Buy |
| 2022-03-15 | 개시 | Ladenburg Thalmann | Buy |
| 2022-01-19 | 개시 | B. Riley Securities | Buy |
| 2021-12-22 | 개시 | Raymond James | Outperform |
| 2021-12-20 | 개시 | SVB Leerink | Outperform |
| 2021-12-15 | 개시 | Wedbush | Outperform |
모두보기
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at Citizens Jmp - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Now Covered by Analysts at Canaccord Genuity Group - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Citizens Jmp - Defense World
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Citizens Initiates Coverage of Compass Therapeutics (CMPX) with Market Outperform Recommendation - Nasdaq
Compass Therapeutics (NASDAQ:CMPX) Trading Down 6%Time to Sell? - MarketBeat
CMPX Analyst Rating Update: Citizens Initiates Coverage with Market Outperform | CMPX Stock News - GuruFocus
This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Cantor Fitzgerald Initiates Compass Therapeutics at Overweight - marketscreener.com
Cantor Fitzgerald initiates Compass Therapeutics stock with Overweight rating By Investing.com - Investing.com UK
Compass Therapeutics stock initiated at Market Outperform by Citizens - Investing.com Canada
The growth track for Compass Therapeutics Inc (CMPX) has changed recently - Setenews
Compass Therapeutics (NASDAQ:CMPX) Sets New 52-Week HighTime to Buy? - MarketBeat
Compass Therapeutics stock hits 52-week high at 5.86 USD By Investing.com - Investing.com Nigeria
Compass Therapeutics (CMPX) Is Up 17.2% After Analyst Highlights Pipeline Progress and Anticipated Tovecimig Data – Has the Bull Case Changed? - Yahoo Finance
Analysts Issue Forecasts for CMPX FY2025 Earnings - Defense World
Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement - Yahoo Finance
A Look at Compass Therapeutics (CMPX) Valuation Following Strong CTX-10726 Preclinical Data and Management Update - Yahoo Finance
Compass Therapeutics (CMPX): Evaluating Valuation After a 55% 1-Month Share Price Surge - sahmcapital.com
Compass Therapeutics (NASDAQ:CMPX) Trading Up 8.1%Time to Buy? - MarketBeat
What analysts say about Compass Therapeutics Inc stockMACD Trading Signals & Free Daily Stock Hotspot Analysis - earlytimes.in
Compass Therapeutics Inc (CMPX) expanding its growth trajectory ahead - Setenews
Q2 Earnings Forecast for CMPX Issued By Leerink Partnrs - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Rating Increased to Strong-Buy at Leerink Partnrs - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Raised to “Strong-Buy” at Leerink Partnrs - Defense World
Published on: 2025-11-28 14:33:59 - moha.gov.vn
What is Leerink Partnrs’ Estimate for CMPX Q2 Earnings? - Defense World
12 Hot Penny Stocks to Invest in Right Now - Insider Monkey
Compass Therapeutics, Inc. (CMPX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Wall Street Analysts Believe Compass Therapeutics, Inc. (CMPX) Could Rally 154.09%: Here's is How to Trade - Finviz
Wall Street Analysts Believe Compass Therapeutics, Inc. (CMPX) Could Rally 154.09%: Here - sharewise.com
Compass Therapeutics to Participate in Upcoming December Investor Events - The Manila Times
Zacks.com featured highlights include Orla Mining, FIGS and Compass Therapeutics - sharewise.com
Will Compass Therapeutics Inc. stock outperform value stocksMarket Growth Review & Verified Technical Trade Signals - newser.com
How Compass Therapeutics Inc. stock performs in weak economy2025 Growth vs Value & Reliable Breakout Forecasts - newser.com
Why Compass Therapeutics Inc. stock is rated strong buyStop Loss & Stepwise Trade Signal Implementation - newser.com
Can Compass Therapeutics Inc. recover in the next quarterJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
Is Compass Therapeutics Inc. stock recession proof2025 Earnings Impact & Short-Term High Return Ideas - newser.com
Compass Therapeutics Inc (CMPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):